Study finds, Single Administration of 5% Povidone-Iodine in
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to evaluate the safety and efficacy of a single, in-office administration of 5% povidone-iodine (PVP-I) compared to artificial tears (AT) for adenoviral conjunctivitis (Ad-Cs).

Patients presenting with presumed adenoviral conjunctivitis were screened.
Inclusion criteria: more than 18 years of age, symptoms less than 4 days and a positive AdenoPlus® test.
Exclusion criteria: thyroid disease, iodine allergy, recent ocular surgery, and ocular findings inconsistent with early-stage Ad-Cs.

Randomization was to a single administration of 5% PVP-I or AT in one eye and examinations on days 1-2, 4, 7, 14 and 21 with conjunctival swabs taken each visit for quantitative polymerase chain reaction.

Results:
--Of 56 patients randomized, 28 had detectable viral titers at baseline.

--Day 4 post-treatment, viral titers in the 5% PVP-I and AT groups were 2.5% ± 2.7% and 14.4% ± 10.5% of peak respectively.

--Severity of participant-reported tearing, lid swelling and redness as well as clinician-graded mucoid discharge, bulbar redness and bulbar edema were lower in the 5% PVP-I group than AT group on Day 4.

--After Day 4, viral titers, severity of signs and symptoms decreased markedly in both groups and no differences between groups were detected.

Finally, pilot findings indicate that in-office 5-% PVP-I treatment may lead to a reduction in viral load and an increase in clinical symptoms and signs in patients suffering from Ad-cs.

Source: https://www.ajo.com/article/S0002-9394(21)00311-1/fulltext?rss=yes
Like
Comment
Share